1. (a) In this section, “opioid antagonist” means:

   1. (1) naloxone hydrochloride; or
   2. (2) any other similarly acting and equally safe drug approved by the federal Food and Drug Administration for the treatment of a drug overdose.

2. (b)

   1. (1) This section applies to:

      1. (i) insurers and nonprofit health service plans that provide coverage for prescription drugs under individual, group, or blanket health insurance policies or contracts that are issued or delivered in the State; and
      2. (ii) health maintenance organizations that provide coverage for prescription drugs under individual or group contracts that are issued or delivered in the State.
   2. (2) An insurer, a nonprofit health service plan, or a health maintenance organization that provides coverage for prescription drugs through a pharmacy benefits manager is subject to the requirements of this section.
3. (c) An entity subject to this section that includes on its formulary an opioid antagonist may apply a prior authorization requirement for an opioid antagonist only if the entity provides coverage for at least one formulation of the opioid antagonist without a prior authorization requirement.

Added by Acts 2017, c. 571, § 4, eff. Jan. 1, 2018; Acts 2017, c. 572, § 4, eff. Jan. 1, 2018.